Two Developments Boost Circassia’s Asthma Products
Circassia Pharmaceuticals, a British company with U.S. headquarters in Morrisville, has received an industry award and signed a group purchasing agreement for its asthma products.
Circassia, a specialty pharmaceutical company focused on respiratory disease, was given the “Innovative Technology Supplier of the Year” award by Vizient, the country’s largest member-driven health care performance improvement company.
The award honors Circassia as a supplier of NIOX technology that has advanced patient care, patient safety and health care worker safety, and delivered solutions that drive incremental improvement to an organization's care or business model.
Circassia serves Vizient’s membership and customer base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers.
“This award reflects their commitment to collaboration and service excellence that helps Vizient’s members meet their goals for supply chain efficiency and cost management,” said Jody Hatcher, president of supply chain services for Vizient.
The award follows Circassia’s signing of a multi-year contract with Vizient in 2018 to provide NIOX asthma-management devices.
NIOX is based on the discovery that patients with allergic airway inflammation, the major cause of asthma, generally have higher than normal levels of nitric oxide in their exhaled breath. By measuring the concentration of exhaled nitric oxide, NIOX enables clinicians to evaluate airway inflammation in asthma patients, aiding diagnosis and helping guide treatment and reduce exacerbations.
The company said that more than 20 million tests have been performed using a NIOX device.
Purchasing Agreement Signed
Circassia was awarded a group purchasing contract by Premier, a healthcare improvement company. The deal gives Premier members special pricing and terms for NIOX asthma diagnosis and management devices.
Premier is an alliance of about 4,000 U.S. hospitals and 165,000 other healthcare providers. Through its integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier aims for better care and outcomes at a lower cost.
“This important Premier contract brings Circassia one step closer to expanding respiratory care options for the estimated 25 million Americans who have been diagnosed with asthma,” said Suzanne Monahan, vice president of Circassia’s NIOX business unit.
Circassia was established in 2006 and has global headquarters in Oxford, England. In 2014 it completed an initial public offering of stock on the London Stock Exchange.
The company moved its U.S. headquarters from New Jersey to Morrisville in 2012. The Morrisville site employs about 50 people in management, customer service, accounting, marketing, training and other administration.